Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu/Bu vs Flu/Mel RIC for Allo-HSCT in AML/MDS
NCT05674539Phase 3Enrolling by invitation
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of melphalan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS). Started Feb 2023; status: enrolling by invitation.
02
Drugs
melphalan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05674539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05674539.